Celldex Therapeutics (NASDAQ:CLDX) Hits New 12-Month Low - What's Next?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares hit a new 52-week low on Monday . The company traded as low as $22.91 and last traded at $23.02, with a volume of 65458 shares. The stock had previously closed at $24.35.

Analysts Set New Price Targets

Several analysts have issued reports on CLDX shares. The Goldman Sachs Group started coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a "neutral" rating and a $45.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Thursday, January 2nd. Citigroup assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $70.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, Wolfe Research cut Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $62.25.

Celldex Therapeutics Trading Down 0.1 %

The firm has a 50-day simple moving average of $26.07 and a two-hundred day simple moving average of $32.24. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -9.46 and a beta of 1.62.

Insider Activity

In related news, CEO Anthony S. Marucci bought 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by insiders.

Institutional Trading of Celldex Therapeutics

Several large investors have recently modified their holdings of CLDX. KBC Group NV lifted its position in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics in the second quarter worth about $76,000. Los Angeles Capital Management LLC lifted its position in shares of Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 638 shares during the last quarter. Quest Partners LLC boosted its stake in Celldex Therapeutics by 1,364.9% during the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 6,879 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 1,504 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.